BIND (RUS) Launches Its New Research & Development Center in Moscow

06 February 2014

BIND (RUS), a wholly owned subsidiary of BIND Therapeutics, Inc of Cambridge, MA, USA (NASDAQ: BIND), today announced the launch of its new R&D Center at Slava Technopark OJSC (Moscow). BIND (RUS) was established as a result of an investment agreement between BIND Therapeutics and RUSNANO OJSC in 2011. The launch will be conducive to the research and development of a series of novel drugs for treatment of cancers and other diseases. In addition, operations of the ultra-modern research and development facility would ensure transfer of the state-of-the-art technologies to Russia.

“BIND (RUS) has been rapidly developing since its establishment late in 2011 as we seek to expand our R&D base. Setting up an ultra-modern laboratory fits in this strategy perfectly, opening up the new BIND technology improvement prospects to us”, Elmira Safarova, BIND (RUS) General Manager, says. “We hope the new opportunities opened for us now would facilitate Russian patients’ gaining access to innovative drugs as soon as possible”.

The Center will focus on development of a new class of highly selective targeted and programmable therapeutics, Accurins™, which are designed utilizing the patented Medicinal Nanoengineering® platform. BIND (RUS) will closely collaborate with the parent company in the research and development of these novel medicines. The Center is fitted up with the state-of-the-art equipment similar to that of BIND Therapeutics flagship laboratories. The special air ventilation system and laboratory layout meet the highest standards of the global biopharmaceutical industry.

As part of the technology transfer, all of BIND (RUS) scientists passed internship at the parent company’s U.S. laboratories. In addition, most of them are experienced in working abroad. Thus, the opening of BIND (RUS) new R&D Center not only contributes to technology transfer and consolidation of the Western and Russian scientific expertise, but also testifies to the fact that favourable conditions for complete realization of the highly qualified personnel potential have taken shape in Russia.

BIND (RUS) is among the leading technology transfer projects in the industry, being one of the first R&D business units of Western pharmaceutical companies in Russia. “The unique research and development implemented here make it an important part of BIND Therapeutics global mission”, said Scott Minick, President of BIND Therapeutics, says. “Talented Russian scientists working at BIND (RUS) make a very valuable contribution to our research and development efforts, and setting up an expanded R&D center will help us to bring potentially life-saving medicines to patients in need.”

BIND (RUS) has become the first branch of BIND Therapeutics outside the United States. The project is intended to accelerate creation of innovative drugs globally, by engaging the unique talents of the Russian scientific school and holding the full-cycle developments in Russia. BIND (RUS) sustainable development has required that a new, bigger R&D center with higher capacity be launched. Slava Technopark OJSC has managed to provide the necessary conditions to BIND (RUS). In addition, the Technopark residents are able not only to place R&D business units on its territory, but also to use the infrastructure of the multi-profile business center and the organizational services, which would enable BIND (RUS) employees to focus on its core lines of business.


BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer.

BIND has announced collaborations with Amgen Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital / Harvard Medical School of BIND’s scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad.

For more information, please visit the company’s web site at

* * *

BIND (RUS) LLC is a Russian company established in 2011 by BIND Therapeutics as a result of the investment agreement with RUSNANO OJSC. BIND (RUS), together with its parent company BIND Therapeutics, engages in development and commercialization of Accurins™, its novel targeted therapeutics. The Russian branch has become the first non-U.S. business unit of BIND Therapeutics. One of the most critical objectives for BIND (RUS) is to transfer the most advanced Western pharmacological and medical technologies to Russia. Since 2013, BIND (RUS) LLC has been a resident of Skolkovo.